Anti-TUSC2 Antibody

Alternative Names: C3orf11, FUS1, PAP, PDAP2, Tumor suppressor candidate 2,Tumor Suppressor 2, Mitochondrial Calcium Regulator, Tumor Suppressor Candidate, PDGFA-Associated Protein, Fusion 1 Protein, Fus-1 Protein

Catalogue Number: AB18-10075-100ug

Size: 100 µg

Background Information

Tumor suppressor candidate 2 (TUSC2) is known to act as a tumor-suppressor and reduced expression of TUSC2 is seen in specific cancers across a number of different tissues. TUSC2 is a target for many microRNAs (miRNAs) that act as modulators of tumorigenesis and tumor progression. In glioblastoma (and possibly in other cancers) TUSC2 acts by up-regulating the level of miR-197 [1]. In Triple Negative Breast Cancer (TNBC) the TUSC2 gene is silenced by miR-138 binding to a unique 5'-UTR target-site, which overlaps with the translation start-site of the transcript. In ovarian cancer miR-663 acts as a potential tumor-promoting miRN through targeting TUSC2.

Product Information

Antibody Type:	Polyclonal	**Host:**	Rabbit
Isotype:	IgG	**Species Reactivity:**	Human, Mouse, Rat
Immunogen:	Full length recombinant human TUSC2		
Format:	100 µg in 100 µl PBS containing 0.02% sodium azide.		
Storage Conditions:	6 months: 4˚C. Long-term storage: -20˚C. Avoid multiple freeze and thaw cycles.		
Applications:	WB IHC IF WB 1:500-2000. IHC 1:50-200. IF 1:50-100.		

Additional Information

Subcellular location:	Mitochondrion	**MW:**	12kDa (Intended as a general guide and does not allow for all isoforms and species variations)
Gene ID	11334	**Uniprot ID:**	O75896

References

1. Xin J, Zhang XK, Xin DY, Li XF, Sun DK, Ma YY, Tian LQ. FUS1 acts as a tumor-suppressor gene by upregulating miR-197 in human glioblastoma. Oncol Rep. 2015;34(2):868–76.